Hyper-connectivity between the left motor cortex and prefrontal cortex is associated with the severity of dysfunction of the descending pain modulatory system in fibromyalgia

Álvaro de Oliveira Franco¹, Camila Fernandes^{1,2}, Paul Vicunha^{1,2}, Janete Bandeira³, Maria Adelia Aratanha⁴, Iraci Lucena da Silva Torres^{2,5}, Felipe Fregni⁶, Wolnei Caumo^{1,2,6,7,8}

¹Laboratory of Pain and Neuromodulation, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.

²Postgraduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

³Laboratory of Biomedical Engineer, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.

⁴Hospital Israelita Albert Einstein, São Paulo, Brazil.

⁵*Translational Nucleus: Pain Pharmacology and Neuromodulation*. Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.

⁶Laboratory of Neuromodulation and Center for Clinical Research Learning, Physics and Rehabilitation Department, Spaulding Rehabilitation Hospital, Boston, MA, USA.

⁷Pain and Palliative Care Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.

⁸Department of Surgery, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

CORRESPONDING AUTHOR: Wolnei Caumo MD, PhD, Laboratory of Pain and Neuromodulation, Hospital de Clínicas de Porto Alegre, Ramiro Barcelos 2350, CEP 90035-003, Bairro Rio Branco, Porto Alegre, RS, Brazil

Phone: (55) 51 - 3359.8083

Fax: (55) 51 - 3359.8083

E-mail: wcaumo@hcpa.edu.br

Short title: Cortical hyper-connectivity is related to dysfunction of the descending pain modulatory system in fibromyalgia.

Number of text pages of the entire manuscript: 36

Number of figures: 3

Number of tables: 3

Abstract

The impaired cortical function likely plays a critical role in chronic pain maintenance and fibromyalgia symptoms. Functional connectivity (FC), as assessed by functional near-infrared spectroscopy (fNIRS), is a promising approach that evaluates cortical activation through hemodynamic response estimation. This study compared the FC of bilateral motor and prefrontal cortices between responders and nonresponders to the conditioned pain modulation test (CPM-test) induced by hand immersion in cold water (0–1°C). We included 37 women with fibromyalgia according to the American College of Rheumatology diagnoses criteria (n = 23 responders to CPM-test and n = 14 nonresponders). After the adjustment for multiple comparisons, we found that nonresponders relative to responders showed higher FC between the left motor cortex (LMC) with the left prefrontal cortex (LPFC) and right prefrontal cortex (RPFC). The psychiatric diagnoses were also positively associated with a higher FC in LMC–LPFC and LMC–RPFC. These results indicate that the increased connectivity between the left motor and bilateral prefrontal cortex might be a neural marker of DPMS dysfunction and an intermediate in the interplay between fibromyalgia and psychiatric disorders.

Keywords: Fibromyalgia; Functional near-infrared spectroscopy (fNIRS); functional connectivity; Conditioned pain modulating.

Introduction

Previous studies have presented evidence of prefrontal cortex (PFC) inhibitory dysfunction in chronic pain syndromes, including fibromyalgia [10]. Furthermore, a growing pool of evidence supports that motor function plays a pivotal role in pain syndrome outcomes [13]. Grey matter loss indicates cortical anatomical abnormalities in fibromyalgia and other pain conditions [35, 37, 38]. Reversal of gray matter loss in the PFC and motor cortex (MC) occurred following therapeutic interventions in chronic pain patients [50, 51, 58, 59]. These findings suggest that chronic pain's underlying pathology is not neurodegenerative and depends structurally and functionally on these cortical areas, which are pivotal for integrating the descending pain modulatory system (DPMS) [22, 45, 66].

DPMS is a set of neural networks that encompasses subcortical structures—e.g., the periaqueductal substance (PAG), rostral medial medulla, nucleus accumbens, mesolimbic reward circuit, and amygdala—, as well as cortical areas—e.g., the MC, the PFC, the primary (S1) and secondary somatosensory cortex (S2), and the cingulate [20, 46]. Among these structures, PFC and the limbic system play a significant role in encoding pain's emotional and contextual components [8, 36, 67]. In contrast, the MC is a significant top-down inhibitory effector, representing a promising area for neuromodulatory intervention [21, 69]. The function of DPMS in fibromyalgia may be assessed by the conditioned pain modulation test (CPM-test) [10], in which higher dysfunction levels correlate with greater fibromyalgia symptom severity and functional disability [60].

In addition to anatomical changes, interest in understanding the functional connectivity (FC) among these cortical areas is rapidly growing. Functional near-infrared spectroscopy (fNIRS) is an imaging method with an excellent temporal resolution that

detects changes in oxygenated (HbO) and deoxygenated hemoglobin levels due to the transient dynamics of neurovascular coupling elicited by neuronal activation, a phenomenon that constitutes the hemodynamic response [3, 52, 56, 69]. Regarding fibromyalgia, studies showed intrinsic connectivity abnormalities—when assessed by resting-state functional connectivity—in the DPMS [9, 68], default mode network [43], executive attention network [42], cognitive control network [34], the insular and cingulate cortices [29], and sensorimotor network [17]. FC uncovered different system-perturbation patterns between groups when analyzed during tasks, after the application of stimuli or when deployed for long-term comparisons between pre-and post-therapeutic interventions, also having a predictive value of patient's treatment response [55, 18, 33].

We conducted this study to test whether FC by fNIRS in fibromyalgia patients might constitute a biomarker of the DPMS dysfunction assessed by the CPM-test, evaluated according to changes in the Numerical Pain Scale (NPS) (0–10 points) during the immersion of the dominant hand in cold water [60]. Therefore, we have compared the FC of bilateral MC and PFC between groups of CPM-test responders and nonresponders in female fibromyalgia patients.

2. Materials and Methods

2.1. Design overview, settings, and participants

This study's protocol was approved by the Institutional Review Board (IRB) of the Hospital de Clinicas de Porto Alegre (HCPA), Brazil, and registered in the Certificate of Presentation of Ethical Appreciation (CAAE registry nº 20170330). We obtained written informed consent from all participants before their inclusion. The study enrollment period ranged from January 2018 to December 2019.

2.2. Recruitment and inclusion and exclusion criteria

We included 44 right-handed literate adult females aged 30 to 65 years with fibromyalgia seen in the outpatients' chronic pain wards of the HCPA and digital media publicity. The diagnosis of fibromyalgia was made according to the American College of Rheumatology (2010–2016) guidelines and confirmed by physicians with more than ten years of experience in chronic pain care. This study included only women due to the higher prevalence of fibromyalgia in women than men [54]. We included only patients with NPS scores greater than or equal to six points. Patients were excluded if they had the following medical conditions: rheumatoid arthritis; systemic lupus erythematosus; or another autoimmune, neurologic, or oncologic disease. Those with current uncompensated clinical disease (e.g., ischemic heart disease, chronic kidney disease, or hepatic disease) or using cannabis or recreational psychotropic drugs in the last six months were similarly excluded.

2.3. Sample size estimation

The post-hoc sample-size calculation revealed that a sample of 37 patients would ensure detection of effect size (f^2) of 0.25 during multiple regression analysis, allowing three predictors based on the consideration of type I and II errors 0.05 and 0.20, respectively [61].

2.4. Dependent and independent variables of primary interest

Ipsi- and contralateral FC between the MC and PFC were the dependent variables. The main factor of interest was the function of DPMS evaluated by the change in the NPS score during the CPM-test.

-----Insert Figure 1 -----

2.5. Instruments and assessments

2.5.1. Functional near-infrared spectroscopy assessment

Cortical activation was evaluated by fNIRS using a NIRx® continuous waveform NirScout® near-infrared spectroscopy device (NIRx Medical Technologies, Glen Head, NY, USA) with a scan rate of 15 Hz and dual-wavelength light-emitting diode sources (760 and 850 nm). We used four sources and 16 detectors spaced about 3 cm apart and placed over the scalp using caps provided by EASYCAP®, with 16 channels in total. Probe localization was established using the international 10/10 electroencephalography system. In our montage, we placed sources in the F3, F4, C3, and C4 locations and detectors in the AF3, F5, FC3, F1, C5, CP3, C1, AF4, F6, FC4, F2, C6, CP4, and C2 locations, respectively. Recordings were made using the NirsStar® version 14.2 software program (NIRx Medical Technologies, Glen Head, NY, USA) and were compiled during a single session for each patient. After adjusting the NIRS cap in the scalp, a black cover was placed over it to reduce the degree of environmental light disturbance. Source-detection calibration and recording-checked signal quality were only confirmed if the calibration returned an assessment of “excellent” quality in at least 14 out of 16 channels and if the other two channels were at least “acceptable” on a qualitative scale based on gain, amplitude, coefficient of variation of noise, and dark noise. The resting-state activity was recorded for seven minutes with patients in a sitting position, during which time they were asked to think about nothing while fixating their gaze on the front wall.

-----Insert Figure 2 -----

2.4.1.1. Functional connectivity analysis

Imaging data were preprocessed using the Brain AnalyzIR® [52] software on the MATLAB (MathWorks, Natick, MA, USA) platform. For the assessment of functional

connectivity values, raw data were downsampled to 1 Hz to adequately address the high level of temporal autocorrelation in fNIRS signals. They were subsequently converted to optical density and then to oxyhemoglobin concentration variation (HbO) using the Beer-Lambert law's modified version [30].

Data were treated through an autoregressive prewhitening model to correct structured noisy and serially correlated error effects (e.g., physiological noise) together with iterative reweighting through a robust regression method addressing outliers (e.g., motion artifacts) with no use of any band/high/low filtering [4, 28]. This method is appropriate for the necessary treatment of serially correlated errors, colored noise, and motion artifacts, dispensing other forms of data processing [4, 5]. In this study, the HbO signal was included in the analysis based on previous reports, which have indicated that this is the most sensitive variable by which to estimate cortical activity via making inferences concerning neurovascular coupling based on hemodynamic response [20, 27, 63, 72,]. Finally, Pearson correlation values were computed for all possible pairs of channels across the time series, and the resulting sample correlation coefficients underwent a Fisher Z-transformation. The Z-values were then averaged for each region of interest (ROI) in each subject (four ROIs $\times$ 37 subjects) [53].

2.4.2. Conditioned pain modulation test

A thermode (30 $\times$ 30 mm) was attached to the skin on the mid-forearm ventral aspect, and the temperature was set at 32°C. The thermode was heated at a rate of 1°C per second up to 52°C, where the temperature was set to drop again thereafter. The CPM-test assessment encompassed three stages: (i) we performed quantitative sensory testing (QST), and subjects reported when the temperature reached a level of pain consistent with

an NPS score of six points (i.e., “6/10 score”) (T0). We replicated this assessment three times and averaged the temperatures to determine the necessary value to achieve an NPS 6/10 score. All three replicates were performed with an interstimulus interval of 40 seconds, and the position of the thermode was slightly altered between trials. (ii) Five minutes after assessing stage I, patients immersed their right hands up to their wrists into the water at a temperature of between 0°C and 1°C for one minute. After 30 seconds of hand immersion, the QST was reapplied on the area of the thermode used in stage I. (iii) The CPM-test score was calculated according to the change in the NPS score retrieved during the cold-water immersion (QST + CPM-test) at the temperature set as 6/10 on the NPS during the initial trial (T0). Patients were considered responders to the CPM-test if they showed a difference of less than zero and nonresponders if the difference was greater than or equal to zero [7]. It is essential to realize that the CPM-test's negative values suggest a higher effect of heterotopic stimulus inhibiting the test stimulus (i.e., “pain inhibits pain”)—in other words, a better function of the DPMS.

2.4.3. Pain measures, psychological assessments, sleep quality, and sociodemographic characteristics

We used the Fibromyalgia Impact Questionnaire (FIQ) [41] to evaluate the impact of life quality symptoms. VAS Analogue Scale assessed the severity of scores in most days of the last three months ranged (VAS, zero to 100mm). The Pain Catastrophizing Scale (PCS) [57] was used to assess the identification of an individual's pain catastrophizing into three dimensions: rumination, magnification, and helplessness. Beck Depression Inventory-II [23] was used to evaluate depressive symptoms, and Central Sensitization Inventory [12] was used to measure symptoms related to central

sensitization syndrome. Over the last month, the sleep quality and sleep patterns were evaluated by the Pittsburgh Sleep Quality Index (PSIQI) [6].

We used a standardized query to assess demographic data and medical comorbidities. We requested to provide information about their age, sex, years of education, and lifestyle habits. Patients also provided information about their health status, including clinical and psychiatric diagnoses, the latter assessed by the Mini-international Neuropsychiatric Interview (M.I.N.I.) [1]. A specific questionnaire evaluates all medications used and their daily doses (e.g., antidepressants, anticonvulsant, hypnotic, analgesics non-opioid and opioid, etc.). We calculated the opioid use by mean morphine-equivalent dose (MED) per day [70]. They were classified with minimal opioid use or no use if the mean daily MED was less than 5 mg or if self-reported opioid use was less than twice a week in the previous 28 days. If they self-reported a mean daily MED equal to or greater than 5 mg for most days for the last three months, they were classified with regular opioid user. Non-opioid analgesic use was defined by analgesic use per week on most days of the previous month. For data analysis, the analgesic use was dichotomized in those used analgesics at least four or fewer days per week or the use for more than four days per week. We adopted this approach because chronic pain patients can change their rescue analgesic use each week depending on pain levels.

Among the efforts to reduce potential sources of bias, all assessments were conducted by researchers with the vast clinical expertise to treat outpatients in a pain clinic, and the diagnostics were done according to the pre-specified criteria described above. Two evaluators with specific training were responsible for all assessments and to apply the standardized protocol to assess the CPM-test and the evaluation using the fNIRS.

2.5. Statistical Analysis

Chi-squared, Fisher's exact tests, and t-tests for independent samples were used to compare categorical and continuous variables between groups. We used the Shapiro-Wilk test to test for normality. The FC was compared by t-test for independent samples in univariate analysis. A multivariate covariance analysis (MANCOVA) model was used to compare FC Z-values among four ROIs taken in pairs (ROIs: left MC, right MC; left PFC, right PFC) between responders and nonresponders adjusted by the following factors: opioid analgesic use (Minimal/no use, or regular opioid use), non-opioid analgesic use, and psychiatric disorder diagnosis (according to the MINI Yes/No). To identify the source of significant differences was used the Bonferroni's Multiple Comparison Test. Statistical significance was set to a p-value of 0.05, 2-tailed. Statistical analysis was conducted in SPSS software version 22.0 (SPSS, Chicago, IL).

3. Results

3.1. Patient characteristics

We enrolled 43 subjects, from which six were excluded, three for missing data, and three due to problems in the fNIRS measures. The final sample was composed of 37 participants (23 responders and 14 nonresponders to CPM-test). The characteristics of the sample and comparative analyses between responders and nonresponders are presented in Table 1. We did not find statistical differences between responders and nonresponders in sociodemographic characteristics, psychological measures, sleep quality, psychotropic medications, and analgesic use. However, nonresponders, compared to responders, presented higher scores in the Visual Analogue Scale ($p=0.02$) and higher psychiatric disorder prevalence ($p=0.03$).

-----Insert Table 1-----

3.2. Univariate analysis according to the spectrum of responders and nonresponders to CPM-test in the FC

According to the spectrum to responders and nonresponders to CPM-test, the mean (Standard Deviation) of cortical FC is presented in Table 2. Nonresponders to CPM-test showed higher FC between the left MC and the left PFC ($t=-2.476$, $p=0.01$) compared to responders. Also, nonresponders presented higher FC levels between the left MC and the right PFC ($t=-2.363$, $p=0.02$).

-----Insert Table 2-----

3.3. Multivariate analysis of the relationship between the FC according to the spectrum of responders and nonresponders to CPM test

The results of the MANCOVA model analysis with dependent variables, the FC between MC and PFC according to the spectrum of responders and nonresponders to the CPM-test, and the number of psychiatric disorders, number of non-opioid analgesics used daily, and number of opioid medications as independent variables, are presented in Table 3. The MANCOVA model using Bonferroni's Multiple Comparison Test revealed a significant relationship between the responders and nonresponders groups and the outcomes related to FC (Hotelling's Trace =1.21, $F(6)=5.47$, $P=0.001$). This analysis presented a power of 0.98.

In the regression analysis, nonresponders showed higher FC between the left MC and the left and right PFC. The left PFC and the right MC displayed increased FC in nonresponders with a borderline statistical significance ($p=0.058$). Cortical FC between the left MC and the right MC was significant on the main effect, with no difference

between groups when considered covariates in the regression analysis. No group effect was observed between the right PFC and right MC.

Psychiatric disorders were associated with FC between left MC-left PFC, left MC-right PFC, left PFC-right MC, and left MC-right MC. In contrast, the regular opioid and non-opioid analgesic use were associated with increased interhemispheric FC in MC. The map of FC across regions of interest in Z-values upon thermal stimulus is shown in Figure 3.

-----Insert Table 3-----

-----Insert Figure 3 -----

4. Discussion

Our findings indicate that nonresponders have an increased FC of left MC with left and right PFC, with a higher FC between left MC and right MC not attributed to the CPM-test but other covariates (i.e., regular opioid use and psychiatric disorders' coexistence). Conversely, non-opioid analgesics are negatively related to inter-hemispheric FC between right MC and left MC. Together, these results suggest that the increased FC between left MC with bilateral PFC is a neural correlate linked to the dysfunction of the DPMS. Thus, our results concatenate the activity imbalance between brain regions with the inhibitory deficiency of the DPMS.

Considering that the CPM-test assesses the potency of the DPMS, the increased FC between left MC with right and left PFC is aligned with the perspective that these findings seem to represent a marker of dysfunction in the inhibitory potency of DPMS. According to an earlier study, the hyper inhibition at the cortical level was associated with

higher dysfunction of DPMS in fibromyalgia [10]. Thus, these areas' hyper-connectivity suggests that the FC may be a marker of cortical network reorganization, and it highlights that this cortical restructuring is associated with DPMS dysfunction. These functional changes may also be processes underpinning central sensitization's pathophysiology, integrating cortical brain networks' deterioration with the corticospinal pain pathways [60]. Consistent with our findings of increased FC in DPMS dysfunction, earlier fMRI studies found that in patients with chronic pain, including chronic low back pain and fibromyalgia, the increased FC between the insula cortex and default mode network, including the medial PFC, is correlated with pain perception intensity [11, 39, 42]. Furthermore, in previous studies, pharmacological and physical interventions to reduce pain also decreased such connectivity, while maneuvers to increase pain increased the FC [25, 39, 43]. The current results and the previous fMRI studies suggest that enhanced FC between the MC and PFC is critical to sustaining chronic pain and fibromyalgia symptoms.

Interestingly, higher connectivity was found in the primary cortical areas involved in pain processing. The increased FC between left MC with PFC areas may indicate a disruption on the mechanism mediated by inhibitory gamma-aminobutyric acid (GABAergic) on the primary motor cortex interneurons, as indexed by short intracortical inhibition (SICI) [15]. Simultaneously, it suggests an up regulatory phenomenon of intracortical inhibitory networks mediated by GABA receptors, a plausible hypothesis according to an earlier study that found an association of increased transient SICI with the deficiency of the DPMS [10]. Hence, these results build in knowledge on the increased connection between MC and PFC's neural network associated with DPMS, which may be a compensatory mechanism to counter-regulate the sustained cortical hyperexcitability in chronic pain. The concept of a physiological adaptation response following a prolonged

system demand supports this hypothesis and may explain the dysfunctional remapping of related system components, which has been observed in other contexts with autonomic, metabolic, and inflammatory systems [24].

The MC inhibits pain by top-down efferences on the DPMS. Thus, these connections may subsidize the MC as a therapeutic target for the transcranial neuromodulation used to treat pain. In the same way, the asymmetric functions of the PFC brain hemispheres can explain the benefits of using excitatory stimulation on the PFC to treat chronic pain or depression, such as the high frequency with repetitive transcranial magnetic stimulation (rTMS) or anodal transcranial direct current stimulation [49, 26]. In contrast, rTMS with low frequency has been used to treat depression when the rTMS is applied to the right PFC. Furthermore, dorsolateral PFC (DLPFC) inhibitory effects on the ipsilateral primary motor cortex (M1) is higher in the left than in the right hemisphere [71], even though right DLPFC has inhibitory effects on the left M1 [44]. Right-handers present stronger effects from the left-to-right MC, which seems to involve excitatory and inhibitory inter-hemispheric activity [73], supporting the idea of an increased activity tone in right-handers' left M1. Our results regarding connectivity between PFC and the left MC may be influenced by the hemispheric dominance when considering that our sample was composed solely of right-hander patients.

The analgesic effect of MC is correlated with the release of endogenous opioids in the anterior cingulate cortex (ACC), insula, and periaqueductal gray matter (PAG) [74]. The anterior MC receives projections from the spinothalamic system transmitting nociceptive information to the cortex, and its activation can be achieved by global pain network modulation. Studies of functional neuroimaging have shown that MC activates supraspinal areas involved in pain perception and emotional appraisal. In a preclinical experiment of neuropathic pain, the MC stimulation reversed the central and peripheral

pain [40], activating the limbic system and PAG and inhibiting the thalamic nuclei and spinal nociceptive neurons [47].

The PFC role in pain processing is integrated with other brain areas, including primary and secondary somatosensory cortices, insular cortex (IC), ACC, and thalamus [2]. The discriminative pain intensity involves connections of the ventrolateral pathways, from the insular cortex to the PFC. Activation of the ACC and medial-PFC (m-PFC) is associated with increased activity on the PAG [48], which is the main control center for descending pain modulation. The PAG originates principally from the PFC cortical projections to the PAG. In contrast, the ventrolateral-PAG is linked to brain regions associated with descending pain modulation, including the ACC, upper pons/medulla [14]. There is a decrease in the glutamate and reductions in the gray matter density in chronic pain in the PFC. Chronic pain may result from disruption of this descending analgesic circuitry that stems from PFC deactivation. Thus, the FC enhancement between PFC and MC in the ipsi- and contralateral hemispheres points towards critical dysfunction on the nociceptive circuitry in fibromyalgia.

Together, these results give insights into generating testable hypotheses regarding improving and optimizing therapy. These results might be applicable for top-down neuromodulation using the tDCS and TMS. These techniques target the M1 and the DLPFC [74]. Variation in FC between the left MC and the PFC in a DPMS-dependent magnitude is a result that highlights the criticality of those cortical areas in pain neuromodulation. These findings also shed light on the mechanism of action of tDCS as a treatment for chronic pain by hinting at the FC abnormalities as potential direct targets and interest variables during follow-up.

It has long been suggested that optically recorded hemodynamic response is not necessarily equivalent to the pyramidal cell activity. Given that cortical layers are constituted by dense interconnections of pyramidal neurons and inhibitory interneurons, it is impossible to differentiate — by estimation of hemodynamic response alone — which information is being outputted by presynaptic neuronal activity [16, 31, 32, 64]. Hence, the higher intensity in a particular ROI implicates a higher presynaptic neural activity independently of its activity quality (e.g., excitatory or inhibitory synaptic signaling). Nevertheless, previous studies on knee osteoarthritis chronic pain patients have found the left MC to display higher corticospinal excitability (assessed by motor-evoked potential) and disinhibited state (attested by shortened cortical silent period), which supports the findings of higher intracortical disinhibition in dysfunctional DPMS attested by non-responsiveness to the CPM test in other studies [65]. Central sensitization in chronic pain is usually linked with insufficient descending inhibition signaling and amplification of afferent signals. These neuroplastic changes are involved in allodynia, hyperalgesia, expanded receptive field, prolonged electrophysiological discharge, and neuronal hyperexcitability [19, 62]. Remarkably, this study's increase in cortical connectivity was associated with a lack of DPMS adaptability, which may suggest an increase in excitatory synaptic signaling and a disinhibited state when taking the above mentioned into account.

The design of this study prevents establishing a causal nexus. This way is required prospective; notwithstanding this limitation, the present work indicates that the cortical FC of non-responder patients is significantly different from responders. We also observed that FC changes correlated with higher opioids use and psychiatric disorders. Although such correlation does not prove direct causality, it is compatible with a causal model in which higher doses of opioids might cause cumulative anatomical–functional changes in

pain pathways. In contrast to opioids, the non-opioid analgesic used was inversely correlated with the connectivity, indicating that they might be more controlled.

In conclusion, these results give insights into understanding the reorganization of neural networks in the main areas involved in pain processing. These results indicate that the hyperconnectivity between the motor and prefrontal cortex might be a neural marker of the DPMS dysfunction and an intermediate in the interplay between fibromyalgia and psychiatric disorders.

DISCLOSURES

Research funding for Brazilian agencies: i) Committee for the Development of Higher Education Personnel—CAPES (grant no. 2018 to P. V. and R. L. for doctorate scholarship). (ii) National Council for Scientific and Technological Development - CNPq (grant nos. 302688/2017-0 and 420826/2018-1 to W. C.). (iii) Postgraduate Research Group at the Hospital de Clínicas de Porto Alegre (grant no. 20170330). Brazilian Innovation Agency (FINEP [Financiadora de Estudos e Projetos]) (process number 1245/13; grant nos. Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS)- 17/2551-0001 087-6 and 17/2551-0001 476-6).

W. C. agrees to be accountable for all aspects of the work, ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Contributorship

Álvaro de Oliveira Franco, Iraci Lucena da S. Torres, Felipe Fregni, and Wolnei Caumo were involved in the study concept and design, acquisition of data or analysis, and interpretation of the data. *Álvaro de Oliveira Franco, Camila Fernandes, Paulo Vicunha, and Maria Adelia Aratanha* were involved in data acquiring, analysis or interpretation. *Álvaro de Oliveira Franco, Felipe Fregni, and Wolnei Caumo* contributed to drafting/revising the manuscript for relevant intellectual content. All authors contributed to the approval of the final version to be published.

Acknowledgments of analysis support: MAA is employed by NIRx Medizintechnik GmbH. All other authors disclose no potential conflicts of interest for the research, authorship, and publication of this article.

REFERENCES

1. Amorim P. Mini International Neuropsychiatric Interview (MINI): validation of a short structured diagnostic psychiatric interview. *Brazilian Journal of Psychiatry*. 2000;22(3):106-115. doi: 10.1590/S1516-44462000000300003.
2. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. *Eur J Pain*. 2005;9(4):463-84. doi:10.1016/j.ejpain.2004.11.001.
3. Bandeira JS, Antunes LDC, Soldatelli MD, Sato JR, Fregni F, Caumo W. Functional Spectroscopy Mapping of Pain Processing Cortical Areas During Non-painful Peripheral Electrical Stimulation of the Accessory Spinal Nerve. *Front Hum Neurosci*. 2019;13:200. doi:10.3389/fnhum.2019.00200.
4. Barker JW, Aarabi A, Huppert TJ. Autoregressive model based algorithm for correcting motion and serially correlated errors in fNIRS. *Biomed Opt Express*. 2013;4(8):1366-79. doi:10.1364/BOE.4.001366.
5. Barker JW, Rosso AL, Sparto PJ, Huppert TJ. Correction of motion artifacts and serial correlations for real-time functional near-infrared spectroscopy. *Neurophotonics*. 2016;3(3):031410. doi:10.1117/1.NPh.3.3.031410.
6. Bertolazi AN, Fagundes SC, Hoff LS, Dartora EG, Miozzo IC, de Barba ME, Barreto SS. Validation of the Brazilian Portuguese version of the Pittsburgh Sleep Quality Index. *Sleep Med*. 2011;12(1):70-5. doi:10.1016/j.sleep.2010.04.020.
7. Botelho LM, Morales-Quezada L, Rozisky JR, Brietzke AP, Torres IL, Deitos A, Fregni F, Caumo W. A Framework for Understanding the Relationship between Descending Pain Modulation, Motor Corticospinal, and Neuroplasticity Regulation Systems in Chronic Myofascial Pain. *Front Hum Neurosci*. 2016;10:308. doi:10.3389/fnhum.2016.00308.

8. Bushnell MC, Ceko M, Low LA. Cognitive and emotional control of pain and its disruption in chronic pain. *Nat Rev Neurosci*. 2013;14(7):502-11. doi:10.1038/nrn3516.
9. Cagnie B, Coppieters I, Denecker S, Six J, Danneels L, Meeus M. Central sensitization in fibromyalgia? A systematic review on structural and functional brain MRI. *Semin Arthritis Rheum*. 2014;44(1):68-75. doi:10.1016/j.semarthrit.2014.01.001.
10. Cardinal TM, Antunes LC, Brietzke AP, Parizotti CS, Carvalho F, De Souza A, da Silva Torres IL, Fregni F, Caumo W. Differential Neuroplastic Changes in Fibromyalgia and Depression Indexed by Up-Regulation of Motor Cortex Inhibition and Disinhibition of the Descending Pain System: An Exploratory Study. *Front Hum Neurosci*. 2019;13:138. doi:10.3389/fnhum.2019.00138.
11. Cauda F, Sacco K, Duca S, Cocito D, D'Agata F, Geminiani GC, Canavero S. Altered resting state in diabetic neuropathic pain. *PLoS One*. 2009;4(2):e4542. doi:10.1371/journal.pone.0004542.
12. Caumo W, Antunes LC, Elkfury JL, Herbstrith EG, Busanello Sipmann R, Souza A, Torres IL, Souza Dos Santos V, Neblett R. The Central Sensitization Inventory validated and adapted for a Brazilian population: psychometric properties and its relationship with brain-derived neurotrophic factor. *J Pain Res*. 2017;10:2109-22. doi:10.2147/JPR.S131479.
13. Chang WJ, O'Connell NE, Beckenkamp PR, Alhassani G, Liston MB, Schabrun SM. Altered Primary Motor Cortex Structure, Organization, and Function in Chronic Pain: A Systematic Review and Meta-Analysis. *J Pain*. 2018;19(4):341-59. doi:10.1016/j.jpain.2017.10.007.
14. Coulombe MA, Erpelding N, Kucyi A, Davis KD. Intrinsic functional connectivity of periaqueductal gray subregions in humans. *Hum Brain Mapp*. 2016;37(4):1514-30. doi:10.1002/hbm.23117.

15. Di Lazzaro V, Pilato F, Dileone M, Ranieri F, Ricci V, Profice P, Bria P, Tonali PA, Ziemann U. GABAA receptor subtype specific enhancement of inhibition in human motor cortex. *J Physiol.* 2006;575(Pt 3):721-6. doi:10.1113/jphysiol.2006.114694.
16. Ekstrom A. How and when the fMRI BOLD signal relates to underlying neural activity: the danger in dissociation. *Brain Res Rev.* 2010;62(2):233-44. doi:10.1016/j.brainresrev.2009.12.004.
17. Flodin P, Martinsen S, Lofgren M, Bileviciute-Ljungar I, Kosek E, Fransson P. Fibromyalgia is associated with decreased connectivity between pain- and sensorimotor brain areas. *Brain Connect.* 2014;4(8):587-94. doi:10.1089/brain.2014.0274.
18. Flodin P, Martinsen S, Mannerkorpi K, Lofgren M, Bileviciute-Ljungar I, Kosek E, Fransson P. Normalization of aberrant resting state functional connectivity in fibromyalgia patients following a three month physical exercise therapy. *Neuroimage Clin.* 2015;9:134-9. doi:10.1016/j.nicl.2015.08.004.
19. Fumal A, Schoenen J. Tension-type headache: current research and clinical management. *Lancet Neurol.* 2008;7(1):70-83. doi:10.1016/S1474-4422(07)70325-3.
20. Gentile E, Ricci K, Delussi M, Brighina F, de Tommaso M. Motor Cortex Function in Fibromyalgia: A Study by Functional Near-Infrared Spectroscopy. *Pain Res Treat.* 2019;2019:2623161. doi:10.1155/2019/2623161.
21. Gentile E, Ricci K, Delussi M, de Tommaso M. Motor cortex function in fibromyalgia: a pilot study involving near-infrared spectroscopy and co-recording of laser-evoked potentials. *Funct Neurol.* 2019;34(2):107-18.
22. Goksan S, Baxter L, Moultrie F, Duff E, Hathway G, Hartley C, Tracey I, Slater R. The influence of the descending pain modulatory system on infant pain-related brain activity. *Elife.* 2018;7. doi:10.7554/eLife.37125.

23. Gomes-Oliveira MH, Gorenstein C, Lotufo Neto F, Andrade LH, Wang YP. Validation of the Brazilian Portuguese version of the Beck Depression Inventory-II in a community sample. *Braz J Psychiatry*. 2012;34(4):389-94. doi:10.1016/j.rbp.2012.03.005.
24. Guidi J, Lucente M, Sonino N, Fava GA. Allostatic Load and Its Impact on Health: A Systematic Review. *Psychother Psychosom*. 2020:1-17. doi:10.1159/000510696.
25. Harris RE, Napadow V, Huggins JP, Pauer L, Kim J, Hampson J, Sundgren PC, Foerster B, Petrou M, Schmidt-Wilcke T, Clauw DJ. Pregabalin rectifies aberrant brain chemistry, connectivity, and functional response in chronic pain patients. *Anesthesiology*. 2013;119(6):1453-64. doi:10.1097/ALN.0000000000000017.
26. Heinze K, Ruh N, Nitschke K, Reis J, Fritsch B, Unterrainer JM, Rahm B, Weiller C, Kaller CP. Transcranial direct current stimulation over left and right DLPFC: Lateralized effects on planning performance and related eye movements. *Biol Psychol*. 2014;102:130-40. doi:10.1016/j.biopsycho.2014.07.019.
27. Hoshi Y, Kobayashi N, Tamura M. Interpretation of near-infrared spectroscopy signals: a study with a newly developed perfused rat brain model. *J Appl Physiol* (1985). 2001;90(5):1657-62. doi:10.1152/jappl.2001.90.5.1657.
28. Huppert TJ. Commentary on the statistical properties of noise and its implication on general linear models in functional near-infrared spectroscopy. *Neurophotonics*. 2016;3(1):010401. doi:10.1117/1.NPh.3.1.010401.
29. Ichesco E, Schmidt-Wilcke T, Bhavsar R, Clauw DJ, Peltier SJ, Kim J, Napadow V, Hampson JP, Kairys AE, Williams DA, Harris RE. Altered resting state connectivity of the insular cortex in individuals with fibromyalgia. *J Pain*. 2014;15(8):815-26 e1. doi:10.1016/j.jpain.2014.04.007.

30. Jobsis FF. Noninvasive, infrared monitoring of cerebral and myocardial oxygen sufficiency and circulatory parameters. *Science*. 1977;198(4323):1264-7. doi:10.1126/science.929199.
31. Jueptner M, Weiller C. Review: does measurement of regional cerebral blood flow reflect synaptic activity? Implications for PET and fMRI. *Neuroimage*. 1995;2(2):148-56. doi:10.1006/nimg.1995.1017.
32. Kahn I, Knoblich U, Desai M, Bernstein J, Graybiel AM, Boyden ES, Buckner RL, Moore CI. Optogenetic drive of neocortical pyramidal neurons generates fMRI signals that are correlated with spiking activity. *Brain Res*. 2013;1511:33-45. doi:10.1016/j.brainres.2013.03.011.
33. Kim SH, Lee MW, Kang MJ, Lee SG, Lee JG, Mun CW. Comparison Analysis between the Medication Efficacy of the Milnacipran and Functional Connectivity of Neural Networks in Fibromyalgia Patients. *Brain Sci*. 2020;10(5). doi:10.3390/brainsci10050295.
34. Kong J, Wolcott E, Wang Z, Jorgenson K, Harvey WF, Tao J, Rones R, Wang C. Altered resting state functional connectivity of the cognitive control network in fibromyalgia and the modulation effect of mind-body intervention. *Brain Imaging Behav*. 2019;13(2):482-92. doi:10.1007/s11682-018-9875-3.
35. Kuchinad A, Schweinhardt P, Seminowicz DA, Wood PB, Chizh BA, Bushnell MC. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain? *J Neurosci*. 2007;27(15):4004-7. doi:10.1523/JNEUROSCI.0098-07.2007.
36. Leknes S, Tracey I. A common neurobiology for pain and pleasure. *Nat Rev Neurosci*. 2008;9(4):314-20. doi:10.1038/nrn2333.
37. Liao X, Mao C, Wang Y, Zhang Q, Cao D, Seminowicz DA, Zhang M, Yang X. Brain gray matter alterations in Chinese patients with chronic knee osteoarthritis pain

based on voxel-based morphometry. *Medicine (Baltimore)*. 2018;97(12):e0145.
doi:10.1097/MD.00000000000010145.

38. Lin C, Lee SH, Weng HH. Gray Matter Atrophy within the Default Mode Network of Fibromyalgia: A Meta-Analysis of Voxel-Based Morphometry Studies. *Biomed Res Int*. 2016;2016:7296125. doi:10.1155/2016/7296125.

39. Loggia ML, Kim J, Gollub RL, Vangel MG, Kirsch I, Kong J, Wasan AD, Napadow V. Default mode network connectivity encodes clinical pain: an arterial spin labeling study. *Pain*. 2013;154(1):24-33. doi:10.1016/j.pain.2012.07.029.

40. Lucas JM, Ji Y, Masri R. Motor cortex stimulation reduces hyperalgesia in an animal model of central pain. *Pain*. 2011;152(6):1398-407. doi:10.1016/j.pain.2011.02.025.

41. Marques AP, Santos AMB, Assumpção A, Matsutani LA, Lage LV, Pereira CAB. Validação da versão brasileira do Fibromyalgia Impact Questionnaire (FIQ). *Revista Brasileira de Reumatologia*. 2006;46(1). doi:10.1590/s0482-50042006000100006

42. Napadow V, LaCount L, Park K, As-Sanie S, Clauw DJ, Harris RE. Intrinsic brain connectivity in fibromyalgia is associated with chronic pain intensity. *Arthritis Rheum*. 2010;62(8):2545-55. doi:10.1002/art.27497.

43. Napadow V, Kim J, Clauw DJ, Harris RE. Decreased intrinsic brain connectivity is associated with reduced clinical pain in fibromyalgia. *Arthritis Rheum*. 2012;64(7):2398-403. doi:10.1002/art.34412.

44. Ni Z, Gunraj C, Nelson AJ, Yeh IJ, Castillo G, Hoque T, Chen R. Two phases of interhemispheric inhibition between motor related cortical areas and the primary motor cortex in human. *Cereb Cortex*. 2009;19(7):1654-65. doi:10.1093/cercor/bhn201.

45. Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. *J Clin Invest*. 2010;120(11):3779-87. doi:10.1172/JCI43766.

46. Ossipov MH, Morimura K, Porreca F. Descending pain modulation and chronification of pain. *Curr Opin Support Palliat Care*. 2014;8(2):143-51. doi:10.1097/SPC.0000000000000055.
47. Pagano RL, Assis DV, Clara JA, Alves AS, Dale CS, Teixeira MJ, Fonoff ET, Britto LR. Transdural motor cortex stimulation reverses neuropathic pain in rats: a profile of neuronal activation. *Eur J Pain*. 2011;15(3):268 e1-14. doi:10.1016/j.ejpain.2010.08.003.
48. Peyron R, Fauchon C. Functional imaging of pain. *Rev Neurol (Paris)*. 2019;175(1-2):38-45. doi:10.1016/j.neurol.2018.08.006.
49. Rego GG, Lapenta OM, Marques LM, Costa TL, Leite J, Carvalho S, Goncalves OF, Brunoni AR, Fregni F, Boggio PS. Hemispheric dorsolateral prefrontal cortex lateralization in the regulation of empathy for pain. *Neurosci Lett*. 2015;594:12-6. doi:10.1016/j.neulet.2015.03.042.
50. Rodriguez-Raecke R, Niemeier A, Ihle K, Ruether W, May A. Brain gray matter decrease in chronic pain is the consequence and not the cause of pain. *J Neurosci*. 2009;29(44):13746-50. doi:10.1523/JNEUROSCI.3687-09.2009.
51. Rodriguez-Raecke R, Ihle K, Ritter C, Muhtz C, Otte C, May A. Neuronal differences between chronic low back pain and depression regarding long-term habituation to pain. *Eur J Pain*. 2014;18(5):701-11. doi:10.1002/j.1532-2149.2013.00407.x.
52. Santosa H, Zhai X, Fishburn F, Huppert T. The NIRS Brain AnalyzIR Toolbox. *Algorithms* 2018;11, 73. doi:10.3390/a11050073.
53. Santosa H, Aarabi A, Perlman SB, Huppert TJ. Characterization and correction of the false-discovery rates in resting state connectivity using functional near-infrared spectroscopy. *J Biomed Opt*. 2017;22(5):55002. doi:10.1117/1.JBO.22.5.055002.

54. Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology to therapy. *Nat Rev Rheumatol.* 2011;7(9):518-27. doi:10.1038/nrrheum.2011.98.
55. Schmidt-Wilcke T, Diers M. New Insights into the Pathophysiology and Treatment of Fibromyalgia. *Biomedicines.* 2017;5(2). doi:10.3390/biomedicines5020022.
56. Scholkmann F, Kleiser S, Metz AJ, Zimmermann R, Mata Pavia J, Wolf U, Wolf M. A review on continuous wave functional near-infrared spectroscopy and imaging instrumentation and methodology. *Neuroimage.* 2014;85 Pt 1:6-27. doi:10.1016/j.neuroimage.2013.05.004.
57. Sehn F, Chachamovich E, Vidor LP, Dall-Agnol L, de Souza IC, Torres IL, Fregni F, Caumo W. Cross-cultural adaptation and validation of the Brazilian Portuguese version of the pain catastrophizing scale. *Pain Med.* 2012;13(11):1425-35. doi:10.1111/j.1526-4637.2012.01492.x.
58. Seminowicz DA, Wideman TH, Naso L, Hatami-Khoroushahi Z, Fallatah S, Ware MA, Jarzem P, Bushnell MC, Shir Y, Ouellet JA, Stone LS. Effective treatment of chronic low back pain in humans reverses abnormal brain anatomy and function. *J Neurosci.* 2011;31(20):7540-50. doi:10.1523/JNEUROSCI.5280-10.2011.
59. Seminowicz DA, Shpaner M, Keaser ML, Krauthamer GM, Mantegna J, Dumas JA, Newhouse PA, Filippi CG, Keefe FJ, Naylor MR. Cognitive-behavioral therapy increases prefrontal cortex gray matter in patients with chronic pain. *J Pain.* 2013;14(12):1573-84. doi:10.1016/j.jpain.2013.07.020.
60. Soldatelli MD, Siepmann T, Illigens BM, Souza dos Santos V, Torres ILS, Fregni F, Caumo W. Mapping of predictors of the disengagement of the descending inhibitory pain modulation system in fibromyalgia: an exploratory study. *British Journal of Pain.* 2020; 204946372092076. doi:10.1177/2049463720920760.

61. Soper D. Free Post-hoc Statistical Power Calculator for Hierarchical Multiple Regression - Free Statistics Calculators [WWW Document]. 2020. Danielsoper.com. URL <https://www.danielsoper.com/statcalc/calculator.aspx?id=17> (accessed 20-09-16).
62. Stefani LC, Leite FM, da Graca LTM, Zanette SA, de Souza A, Castro SM, Caumo W. BDNF and serum S100B levels according the spectrum of structural pathology in chronic pain patients. *Neurosci Lett.* 2019;706:105-9. doi:10.1016/j.neulet.2019.05.021.
63. Strangman G, Culver JP, Thompson JH, Boas DA. A quantitative comparison of simultaneous BOLD fMRI and NIRS recordings during functional brain activation. *Neuroimage.* 2002;17(2):719-31.
64. Tanosaki M, Sato C, Shimada M, Iguchi Y, Hoshi Y. Effect of stimulus frequency on human cerebral hemodynamic responses to electric median nerve stimulation: a near-infrared spectroscopic study. *Neurosci Lett.* 2003;352(1):1-4. doi:10.1016/j.neulet.2003.08.055.
65. Tarrago Mda G, Deitos A, Brietzke AP, Vercelino R, Torres IL, Fregni F, Caumo W. Descending Control of Nociceptive Processing in Knee Osteoarthritis Is Associated With Intracortical Disinhibition: An Exploratory Study. *Medicine (Baltimore).* 2016;95(17):e3353. doi:10.1097/MD.00000000000003353.
66. Tracey I, Mantyh PW. The cerebral signature for pain perception and its modulation. *Neuron.* 2007;55(3):377-91. doi:10.1016/j.neuron.2007.07.012.
67. Tracey I. Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans. *Nat Med.* 2010;16(11):1277-83. doi:10.1038/nm.2229.
68. Truini A, Tinelli E, Gerardi MC, Calistri V, Iannuccelli C, La Cesa S, Tarsitani L, Mainero C, Sarzi-Puttini P, Cruccu G, Caramia F, Di Franco M. Abnormal resting state

functional connectivity of the periaqueductal grey in patients with fibromyalgia. *Clin Exp Rheumatol*. 2016;34(2 Suppl 96):S129-33.

69. Uceyler N, Zeller J, Kewenig S, Kittel-Schneider S, Fallgatter AJ, Sommer C. Increased cortical activation upon painful stimulation in fibromyalgia syndrome. *BMC Neurol*. 2015;15:210. doi:10.1186/s12883-015-0472-4.

70. Von Korff M, Saunders K, Thomas Ray G, Boudreau D, Campbell C, Merrill J, Sullivan MD, Rutter CM, Silverberg MJ, Banta-Green C, Weisner C. De facto long-term opioid therapy for noncancer pain. *Clin J Pain*. 2008;24(6):521-7. doi:10.1097/AJP.0b013e318169d03b.

71. Wang Y, Cao N, Lin Y, Chen R, Zhang J. Hemispheric Differences in Functional Interactions Between the Dorsal Lateral Prefrontal Cortex and Ipsilateral Motor Cortex. *Front Hum Neurosci*. 2020;14:202. doi:10.3389/fnhum.2020.00202.

72. Zama T, Shimada S. Simultaneous measurement of electroencephalography and near-infrared spectroscopy during voluntary motor preparation. *Sci Rep*. 2015;5:16438. doi:10.1038/srep16438.

73. Ziemann U, Hallett M. Hemispheric asymmetry of ipsilateral motor cortex activation during unimanual motor tasks: further evidence for motor dominance. *Clin Neurophysiol*. 2001;112(1):107-13. doi:10.1016/s1388-2457(00)00502-2.

74. Zortea M, Ramalho L, Alves RL, Alves C, Braulio G, Torres I, Fregni F, Caumo W. Transcranial Direct Current Stimulation to Improve the Dysfunction of Descending Pain Modulatory System Related to Opioids in Chronic Non-cancer Pain: An Integrative Review of Neurobiology and Meta-Analysis. *Front Neurosci*. 2019;13:1218. doi:10.3389/fnins.2019.01218.

Figure Legends

Figure 1. Timeline assessments. CPM-test: condition pain modulation test; fNIRS: functional near-infrared spectroscopy.

Figure 2. fNIRS montage. **A.** Sources and detectors were arrayed in 10-10 system. AFF3h, FCC3h, AFF4h, FCC4h correspond to short-distance channels. **B.** Illustrative demonstration of near-infrared diffuse reflection path between source and receptor.

Figure 3. Heatmap visualization of FC across regions of interest in Z-values. Nonresponders represented higher connectivity than responders between LMC and bilateral PFC. **A.** Mean FC by region of interest in CPM-test responders. **B.** Mean FC by region of interest in CPM-test nonresponders. FC: functional connectivity; CPM-test: conditioned pain modulation test. LPFC: Left prefrontal cortex; LMC: Left motor cortex; RPFC: Right prefrontal cortex; RMC: Right motor cortex. * $p < 0.05$.

Table 1. Demographic and clinical characteristics of the study sample. Values are given as the mean (SD) or frequency (n=37).

	Responder (n=23)	NonResponder (n=14)	P-value
Age (years)	48.00 (9.587)	51.07 (9.988)	0.36
Body index	28.56 (4.36)	30.00 (4.99)	0.37
Education (years)	13.52 (4.220)	10.86 (4.849)	0.09
Smoking Yes/No	6 (26.08%) /17	3 (21.42%) /11	0.53
Clinical Comorbidity (Yes%) /No	18 (78.26%) /5	9 (64.28%) /5	0.61
Hypertension (Yes)	9 (39.130%)	7 (50%)	
Diabetes (Yes)	2 (8.695%)	1 (7.142%)	
Thyroid disease (Yes)	3 (13.043%)	5 (35.714%)	
Asthma (Yes)	6 (26.086%)	1 (7.142%)	
Pain, sleep quality and psychological measures			
Beck Depression Inventory	24.32 (13.10)	25.50 (10.54)	0.77
Central Sensitization Inventory	62.35 (22.49)	68.36 (14.0)	0.37
Pain Catastrophizing Scale	33.78 (10.617)	35.43 (13.72)	0.68
Fibromyalgia Questionnaire M2	64.77 (21.28)	70.47(20.11)	0.49
Pittsburgh Sleep Quality Index	13.00 (3.830)	12.64 (4.03)	0.79
American College of Rheumatology - 2016			
Revisions to the 2010/2011 Fibromyalgia Diagnostic Criteria	23.22 (2.844)	23.07 (4.16)	0.90
Visual Analogue Scale (0–10)	8.19 (1.312)	9.13 (0.921)	0.02
Number of days of non-opioid analgesic used per week in the last month (≥ 4 days)**	8 (34.8%)	6 (42.9%)	0.44
Acetaminophen/Dipirone (Yes)	11 (47.8%)	5 (35.7%)	
Dorflex® (Yes)	12 (52.2%)	9 (64.3%)	
Cyclobenzaprine	10 (43.5%)	1 (7.1%)	
NSAID (Yes)	6 (26.1%)	5 (35.7%)	
Use opioid analgesic use			
Minimal or no use	18 (78.3%)	10 (71.4%)	0.46
Regular opioid use	5 (21.7%)	4 (28.7%)	
Psychiatric disorder according to the MINI (Yes/No) *	18 (78.26%)/5	13 (92.857%)/1	0.03
Major Depressive Disorder	14 (60.869%)	13 (92.857%)	
Generalized Anxiety Disorder	11 (47.83%)	3 (21.43%)	
Panic Disorder	5 (21.74%)	2 (14.28%)	
Active use of central nervous system active medication Yes/No**	18 (78.3%)/5	11 (78.6%)/3	0.66
Antidepressant tricyclic (yes)	2 (8.695%)	5 (35.714%)	
Antidepressant dual (Yes)	11 (47.826%)	4 (28.571%)	

Antidepressants selective serotonin reuptake inhibitors (yes)	8 (34.782%)	6 (42.857%)
Antipsychotic (yes)	1 (4.347%)	2 (14.285%)
Anticonvulsant (yes)	6 (26.086%)	4 (28.571%)
Hypnotic (yes)	6 (26.086%)	4 (28.571%)

*NSAID: nonsteroidal anti-inflammatory drugs; MINI: mini-international Neuropsychiatric Interview. **Some patients were using more than one type of drug; *Some patients were more than one psychiatric disorder. \$ Minimal/no use (mean daily MED <5 mg or less than twice a week (including no use). Regular or higher dose of opioids (Mean daily MED ≥5 mg). Dorflex® (300 mg of dipyrrone monohydrate, 35 mg of orphenadrine citrate and 50 mg of anhydrous caffeine).*

Table 2. Relationship of the outcomes and the main interest factor according to the spectrum of responders and non-responders to CPM-test. Data are presented as the mean (standard deviation) (n=37).

Region of interest connectivity	Responders	Nonresponders	t	p-value
Left prefrontal cortex – Left motor cortex	0.607 (0.165)	0.738 (0.138)	-2.476	0.01
Left prefrontal cortex – Right prefrontal cortex	0.728 (0.189)	0.778 (0.133)	-0.861	0.39
Left prefrontal cortex – Right motor cortex	0.521 (0.163)	0.608 (0.085)	-1.831	0.07
Left motor cortex – Right prefrontal cortex	0.524 (0.165)	0.648 (0.131)	-2.363	0.02
Left motor cortex – Right motor cortex	0.518 (0.224)	0.610 (0.149)	-1.370	0.17
Right prefrontal cortex – Right motor cortex	0.544 (0.199)	0.617 (0.133)	-1.214	0.23

Table 3. MANCOVA analysis of the relationship between the FC according to the spectrum of responders or non-responders according to change in NPS (0-10) during the CPM-test (n=37).

(A) Main effects							
Dependent Variable	Type III Sum of Squares	df	Mean Square	F	Sig.	Partial Eta Squared	
Left prefrontal cortex – Left motor cortex	0.372 ^a	4	0.093	4.711	0.004	0.371	
Left prefrontal cortex – Right prefrontal cortex	0.186 ^b	4	0.047	1.739	0.166	0.179	
Left prefrontal cortex – Right motor cortex	0.179 ^c	4	0.045	2.506	0.062	0.239	
Left motor cortex – Right prefrontal cortex	0.305 ^d	4	0.076	3.696	0.014	0.316	
Left motor cortex – Right motor cortex	0.482 ^e	4	0.120	3.884	0.011	0.327	
Right prefrontal cortex – Right motor cortex	0.183 ^f	4	0.046	1.507	0.224	0.159	
B. Coefficient							
Dependent Variable	B	Std. Error	t	Sig.	CI 95%		
Left prefrontal cortex – Left motor cortex							
<i>Intercept</i>	0.438	0.100	4.381	0.000	(0.234 to 0.641)		
Responders/Nonresponders	-0.134	0.048	-2.803	0.009	(-0.231 to -0.037)		
Psychiatric disorder according to the MINI (Yes)	0.266	0.090	2.943	0.006	(0.082 to 0.449)		
Regular or higher dose of opioids	0.045	0.035	1.280	0.210	(-0.027 to 0.117)		
Number of days of non-opioid analgesic used per week in the last month (≥ 4 days)	-0.001	0.015	-0.076	0.940	(-0.031 to 0.029)		
Left prefrontal cortex – Right prefrontal cortex							
<i>Intercept</i>	0.647	0.116	5.567	0.000	(0.410 to 0.884)		
Responders/Nonresponders	-0.054	0.055	-0.969	0.340	(-0.167 to 0.059)		
Psychiatric disorder according to the MINI (Yes)	0.124	0.105	1.181	0.246	(-0.090 to 0.338)		
Regular opioid use	-0.077	0.041	-1.872	0.070	(-0.160 to 0.007)		
Number of days of non-opioid analgesic used per week in the last month (≥ 4 days)	0.014	0.017	0.852	0.401	(-0.020 to 0.049)		
Left prefrontal cortex – Right motor cortex							
<i>Intercept</i>	0.388	0.095	4.085	0.000	(0.195 to 0.582)		
Responders/Nonresponders	-0.089	0.045	-1.965	0.058	(-0.181 to -0.003)		
Psychiatric disorder according to the MINI (Yes)	0.197	0.086	2.301	0.028	(0.023 to 0.372)		
Regular opioid use	0.022	0.033	0.662	0.513	(-0.046 to 0.090)		
Number of days of non-opioid analgesic used per week in the last month (≥ 4 days)	0.000	0.014	-0.033	0.974	(-0.029 to 0.028)		
Left motor cortex – Right prefrontal cortex							

<i>Intercept</i>	0.378	0.102	3.702	0.001	(0.170 to 0.585)
Responders/Non-responders	-0.127	0.049	-2.615	0.013	(-0.227 to -0.028)
Psychiatric disorder according to the MINI (Yes)	0.262	0.092	2.845	0.008	(0.074 to 0.450)
Regular or higher dose of opioids	0.016	0.036	0.450	0.656	(-0.057 to 0.089)
Number of days of non-opioid analgesic used per week in the last month (≥ 4 days)	-0.008	0.015	-0.539	0.594	(-0.038 to 0.022)
Left motor cortex – Right motor cortex					
<i>Intercept</i>	0.278	0.125	2.223	0.033	(0.023 to 0.533)
Responders/Nonresponders	-0.097	0.060	-1.622	0.115	(-0.219 to 0.025)
Psychiatric disorder according to the MINI (Yes)	0.351	0.113	3.107	0.004	(0.121 to 0.582)
Regular opioid use	0.098	0.044	2.233	0.033	(0.009 to 0.188)
Number of days of non-opioid analgesic used per week in the last month (≥ 4 days)	-0.040	0.018	-2.199	0.035	(-0.077 to -0.003)
Right prefrontal cortex – Right motor cortex					
<i>Intercept</i>	0.382	0.124	3.089	0.004	(0.130 to 0.634)
Responders/Nonresponders	-0.076	0.059	-1.278	0.210	(-0.196 to 0.045)
Psychiatric disorder according to the MINI (Yes)	0.202	0.112	1.805	0.081	(-0.026 to 0.430)
Regular opioid use	0.010	0.044	0.241	0.811	(-0.078 to 0.099)
Number of days of non-opioid analgesic used per week in the last month (≥ 4 days)	0.015	0.017	0.898	0.376	(-0.030 to 0.043)

MINI: mini-international Neuropsychiatric Interview.

^a R^2 adjusted = 0.29

^b R^2 adjusted = 0.08

^c R^2 adjusted = 0.14

^d R^2 adjusted = 0.23

^e R^2 adjusted = 0.24

^f R^2 adjusted = 0.05

- ✓ Standardized questionnaire on demographic data and health status, psychiatric and analgesic medications
- ✓ Pain VAS (0-10) and analgesic use weekly
- ✓ Fibromyalgia Impact Questionnaire (QIF)
- ✓ Brazilian Pain Profile Pain Screen (BP-PCS)
- ✓ Mini-international Neuropsychiatric Interview (M.I.N.I.)
- ✓ Brazilian Portuguese Beck Depression Inventory-II (BDI-II)
- ✓ Brazilian Portuguese Pain Catastrophizing Scale (BP-PCS);
- ✓ Pittsburgh Sleep Quality Index (PSQI)
- ✓ Central Sensitization Inventory

fNIRS

Functional connectivity:

Recording during 7 minutes

Test stimuli (T0)

Conditioning stimuli (T1)

Average of three assessment to define the temperature to produce pain 6/10 on NPS (0-10)= T0 during the QST

CPM-test = NPS (T1) – NPS (T0)

CPM-test ≥ 0: nonresponders

CPM-test < 0: responders

Figure

A **B**

Figure

A Mean FC in CPM-test responders.

B Mean FC in CPM-test nonresponders.

Figure